CellBion (A308430) Stock Overview
Engages in the research and development of radiopharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
A308430 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
CellBion Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩27,600.00 |
| 52 Week High | ₩42,200.00 |
| 52 Week Low | ₩14,420.00 |
| Beta | 0 |
| 1 Month Change | -16.74% |
| 3 Month Change | 16.95% |
| 1 Year Change | 35.63% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 33.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| A308430 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 3.0% | -1.0% | -1.6% |
| 1Y | 35.6% | 53.5% | 106.8% |
Return vs Industry: A308430 underperformed the KR Pharmaceuticals industry which returned 53.5% over the past year.
Return vs Market: A308430 underperformed the KR Market which returned 106.8% over the past year.
Price Volatility
| A308430 volatility | |
|---|---|
| A308430 Average Weekly Movement | 14.6% |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in KR Market | 15.4% |
| 10% least volatile stocks in KR Market | 4.2% |
Stable Share Price: A308430's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A308430's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 57 | Kweon Kim | www.cellbion.co.kr |
CellBion Co., Ltd. engages in the research and development of radiopharmaceutical products. Its clinical stage pipeline includes 177Lu-PSMA-DGUL, indicated for prostate cancer radiotherapy, currently under Phase 2 clinical stage; 225Ac-Antibody, indicated for multiple cancer types, currently under pre-clinical stage; 225Ac-DGUL, indicated for prostate cancer radiotherapy, currently under pre-clinical stage; 68Ga-Nota-MSA, indicated for cardiovascular disease diagnosis, currently under Phase 2 clinical stage; 99mTc-MSA-ICG, indicated for lymphoscintigraphy SLN mapping, currently under Phase 1 clinical stage; and 68Ga-NGUL, indicated for prostate cancer diagnosis, currently under Phase 2 clinical stage. It is also involved in the development of preclinical stage pipeline comprising 68 Ga-FAP, indicated for solid tumors diagnosis; 225 Ac-FAP, indicated for solid tumors radiotherapy; and peptide-based radioligand therapy and antibody-radionuclide conjugates for undisclosed indications.
CellBion Co., Ltd. Fundamentals Summary
| A308430 fundamental statistics | |
|---|---|
| Market cap | ₩358.00b |
| Earnings (TTM) | -₩7.55b |
| Revenue (TTM) | ₩2.13b |
Is A308430 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A308430 income statement (TTM) | |
|---|---|
| Revenue | ₩2.13b |
| Cost of Revenue | ₩2.06b |
| Gross Profit | ₩70.73m |
| Other Expenses | ₩7.63b |
| Earnings | -₩7.55b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -588.77 |
| Gross Margin | 3.32% |
| Net Profit Margin | -354.71% |
| Debt/Equity Ratio | 5.9% |
How did A308430 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/17 10:16 |
| End of Day Share Price | 2026/03/17 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CellBion Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.